Condition: Bone Resorption · Sponsor: Teknimed
A Post-Market Clinical Follow-Up (PMCF) Study to collect clinical data on safety and performance of all TEKNIMED Bone Substitute range of products: CERAFORM, TRIHA+, NANOGEL, and all their private labels. TEKNIMED bone substitutes are legacy products, some marketed for more than 20 years. Their performance and safety have already been demonstrated by Post-Market Surveillance and previous clinical studies. The current Post-Market Clinical Follow-Up study aims to confirm these claims by collecting data in a "real-life" setting. The study is a retrospective and prospective global, single arm, non-controlled, multicentric, prospective observational study. Patients will be followed as per local standard medical care of the sites.
This description comes directly from the study's public registry record.
Solange VAN DE MOORTELE, PhD · +33534252679 · s.vandemoortele@teknimed.com
Always discuss trial participation with your own doctor first.
| Pôle Rachis Hôpital Privé d'Eure et Loir | Mainvilliers, Eure et Loir, France | Recruiting |
| Hôpital Joseph Ducuing | Toulouse, Haute Garonne, France | Recruiting |
| Clinique Médipole Garonne | Toulouse, Haute Garonne, France | Recruiting |
| CHRU Brabois | Nancy, Meurthe et Moselle, France | Recruiting |
| Clinique du Pré | Le Mans, Sarthe, France | Recruiting |
| OCM Klinik GmbH | München, Bavaria, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06374342